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extensive bacteriocin gene 
shuffling in the Streptococcus 
bovis/Streptococcus equinus 
complex reveals gallocin D 
with activity against vancomycin 
resistant enterococci
Daragh Hill1,2,3, Paula M. O’Connor2,3, Eric Altermann4,5, Li Day4, Colin Hill3,6, 
catherine Stanton2,3 & R. Paul Ross3,6*
Streptococcus gallolyticus LL009 produces gallocin D, a narrow spectrum two component bacteriocin 
with potent activity against vancomycin-resistant enterococci. Gallocin D is distinct from gallocin 
A, a separate two component bacteriocin produced by S. gallolyticus. Although the gene clusters 
encoding gallocin A and gallocin D have a high degree of gene synteny, the structural genes are highly 
variable and appear to have undergone gene shuffling with other streptococcal species. Gallocin D was 
analysed in laboratory-based experiments. The mature peptides are 3,343 ± 1 Da and 3,019 ± 1 Da and 
could be readily synthesized and display activity against a vancomycin resistant Enterococcus strain 
EC300 with a MIC value of 1.56 µM. Importantly, these bacteriocins could contribute to the ability of S. 
gallolyticus to colonize the colon where they have been associated with colorectal cancer.
With the rise of antibiotic resistant pathogens and the decreasing number of novel antibiotics, the search for 
alternative antimicrobials is of increasing  importance1. Bacteriocins are potential antimicrobial candidates and 
consist of different classes of ribosomally-synthesized antimicrobial peptides which are either narrow or broad 
 spectrum2. Narrow spectrum bacteriocins are of particular interest as targeted therapeutics since they could be 
expected to have minimal impact on resident  microbiota3,4. Bacteriocin-producing bacteria have been isolated 
from a range of sources including food, skin, and the gastrointestinal tracts of both animals and  humans5. Among 
the functions attributed to bacteriocins are competition, quorum sensing and host  signalling6. They are classified 
into multiple types; class I are lantibiotics such as nisin which are subject to post-translational modification, 
and class II that are unmodified or cyclic peptides. The class II bacteriocins are divided into several  subgroups7.
Class IIb are two-peptide bacteriocins where the two components are required for maximal activity. The 
structural genes encoding them are usually adjacently located, together with a gene encoding an immunity 
protein that protects the cell from being killed by its own  bacteriocin8. Class IIb bacteriocin operons usually 
also contain an ABC transporter and an accessory protein. Both peptides are synthesised as pre-peptides with 
a leader sequence at the N terminal that is cleaved during export at a GG motif to produce the extracellular 
mature active peptide. This cleavage is performed by the ABC transporter or a peptidase which recognises the 
leader sequence, and transports the peptide across the cell membrane. Two-component bacteriocins require 
both peptides for optimal activity and both peptides interact with one another at the same target site to form 
one antibacterial unit. The mode of action of these bacteriocins involves the binding of the peptides to a target 
in the cell membrane, leading to pore formation causing leakage and cell death.
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Streptococcus gallolyticus ssp gallolyticus, formerly described as S. bovis biotype I, is an opportunistic patho-
gen associated with infectious endocarditis (IE) and colorectal cancer (CRC)9. It is hypothesized that altered 
conditions in the colon associated with cancer provide an environment in which S. gallolyticus is able to thrive 
and colonise. This ability is linked to the production of a two component bacteriocin gallocin, for clarification 
referred to as gallocin A. In one study, using a murine model of CRC, colonisation of tumour bearing mice by 
S. gallolyticus UCN34 was mediated by production of gallocin A encoded by two structural genes, gallo_2020 
and gallo_2021, hereafter designated gllA1 and gllA210. The bacteriocin is active against enterococci, potentially 
creating a niche in the colon for S. gallolyticus colonisation. An S. gallolyticus UCN34 in which gllA1 and gllA2 
were knocked out lacked this colonisation advantage in tumour bearing mice. In this study, we describe a strain 
of S. gallolyticus which harbours distinct structural genes in place of gllA1 and gllA2. These structural genes are 
similar to genes encoding a bacteriocin produced by Streptococcus infantarius ssp infantarius (Sii)11.
Streptococcus gallolyticus and S. infantarius are both members of the Streptococcus bovis/Streptococcus equi-
nus complex (SBSEC) which is divided into seven subspecies; S. gallolyticus, S. infantarius, S. gallolyticus ssp 
macedonicus (Sgm), S. gallolyticus ssp pasteurianus (Sgp), Streptococcus lutetiensis, Streptococcus alactolyticus, 
and S. equinus12,13. SBSEC members have been isolated from human, animal and food sources, with an esti-
mated carriage rate of 5% in healthy adults. S. gallolyticus has been linked with IE and CRC in humans, while S. 
infantarius is found in fermented foods, predominantly in sub-Saharan  Africa14–18. S. infantarius has also been 
linked to CRC in an African cohort, although this did not correlate to consumption of traditional fermented 
food containing species of S. infantarius. This suggests a separation between commensal, opportunistic patho-
gen, and food  lineages19,20. The SBSEC genomes have been studied for their ability to colonise in their associated 
niche, for example some strains such as S. gallolyticus retain tannin degrading abilities associated with survival 
in ruminant  animals18,21,22. Other strains such as S. infantarius and S. gallolyticus ssp pasteurianus have lost this 
ability and have undergone a genome reduction associated with an adaption to the dairy  environment18. This 
has been discussed at length for members of the SBSEC, and it has been suggested that isolation source is associ-
ated with strain  lineage23,24. S. gallolyticus strains have retained the largest genomes and most diverse functional 
capabilities and have been found in both healthy individuals and patients with underlying disease. It has been 
found in 74% of CRC patients and preferentially associates with tumour  tissue9,25.
This study analysed class IIb bacteriocins in S. gallolyticus and S. infantarius and highlights the ability of these 
strains to adapt to their niche. Based on the discovery of bacteriocin structural genes in our new isolate S. gallo-
lyticus LL009, we completed an in silico screen on available sequences of other SBSEC members. This analysis 
revealed that a similar bacteriocin operon is present in each S. gallolyticus strain analysed, but S. gallolyticus 
LL009 contains distinct structural and immunity genes. The bacteriocin, termed gallocin D, is a variant of a 
bacteriocin produced by another dairy isolate S. infantarius  LP9011. A similar bacteriocin operon is also present 
in members of the related S. infantarius. The bacteriocin produced by S. gallolyticus LL009, that we designate 
gallocin D, was synthesized and analysed for activity against related S. gallolyticus strain and other clinically-
relevant pathogens. It was found to have activity against clinically important pathogens, including Streptococcus 
pneumoniae, vancomycin resistant enterococci and another S. gallolyticus strain.
Results
Identification of the bacteriocin produced by Streptococcus gallolyticus LL009. Streptococcus 
gallolyticus LL009 (Sgg LL009) was isolated from raw goat milk sourced in New Zealand; milk samples were 
stored at − 20 °C until processing. The strain was initially isolated by streaking 10 µl of milk onto Streptococcus 
thermophilus selective agar that was incubated at 42 °C for 24 h. To test for bacteriocin production, individual 
isolates were streaked onto BHI agar and incubated overnight at 37 °C, aerobically. When overlaid with Lb. del-
brueckii ssp bulgaricus LMG 6,901, zones of inhibition were observed around the colonies of Sgg LL009 (Fig. 1). 
Figure 1.  Detection of the 3,021.29 Da gallocin D2 peptide by MALDI-TOF MS from colonies on a plate. Inset 
shows the antimicrobial activity of S. gallolyticus LL009 against L. bulgaricus LMG6901.
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No antimicrobial activity was observed when a cell-free supernatant was tested by well diffusion assay, but a zone 
of clearing was observed when cell-containing broth was used in this assay. Inhibitory activity was restored to the 
cell free supernatant when Tween80 was added. We designated this bacteriocin activity as gallocin D, pending 
further analysis.
Sgg LL009 was tested for the production of capsular exopolysaccharide (EPS), a feature of some S. gallolyticus 
strains. Colonies were positive for the loop touch test and were white on ruthenium red supplemented medium, 
indicating a ropy type  EPS26,27. On sucrose supplemented medium, a large amount of mucous type EPS was 
produced.
Sgg LL009 was not completely resistant to any antibiotic tested (Table 1). It is non-proteolytic in that no zones 
of clearing were observed surrounding colonies on 10% (w/v) reconstituted skim milk (RSM). A green coloura-
tion was observed surrounding cells on blood agar for hemolysis testing, indicative of alpha hemolysis. Alpha 
hemolysis is defined as bruising of the red blood cells and not true lysis.
In silico analysis of Streptococcus gallolyticus LL009. Following draft genome sequencing of the gal-
locin D producer Sgg LL009, in silico analysis was performed using BAGEL4 and antiSMASH to identify bacte-
riocin-associated  genes28,29. A single bacteriocin operon was identified in Sgg LL009 that consists almost entirely 
of genes also found in the gallocin A operon of strain S. gallolyticus DSM16831 (Fig. 2A). The predicted function 
of each gene is shown in Table 2. However, the bacteriocin structural genes (gllD1 and gllD2) and that encoding 
the immunity protein (gllDI) do not have homologs in the gallocin A producing S. gallolyticus. These genes are 
homologous to genes found in the infantaricin ABCDEFG bacteriocin cluster from S. infantarius LP90 (Fig. 2B). 
The predicted structural genes in the LL009 operon are variants of infantaricin A, where gllD1 shares 98% amino 
acid identity with infA1, while gllD2 shares 90% amino acid identity with infA2. The predicted molecular weight 
of gllD2, 3,019.54 Da, is consistent with the 3,021.29 Da mass found by MALDI TOF mass spectrometry analysis 
(Fig. 1). This mass could not be matched to any known bacteriocin in the bactibase database. 
Nine strains of S. gallolyticus and S. infantarius with available genomic data (including Sgg LL009) were 
analysed for the presence of bacteriocin operons (Table 3). The ABC transporters are highly conserved in both 
species, with 97% amino acid identity (Fig. 3). Infantaricin A is encoded by the infantaricin ABCDEFG bacte-
riocin operon in S. infantarius LP90. Twelve structural bacteriocin genes can be identified in the operon, ten of 
which make up five two-peptide  bacteriocins11. There is significant variation in the structural gene arsenal of 
each strain. Each previously sequenced strain of S. gallolyticus contained the gallocin A structural genes, gllA1and 
gllA2, while all S. infantarius strains other than CJ18 contained a homolog of infantaricin C. The infantaricin 
C bacteriocin genes, infC1 and infC2, in S. infantarius LP90 have 66% and 78% identity with gllA1 and gllA2, 
respectively. One strain of S. gallolyticus ssp macedonicus has gllA2 next to a gene with 60% identity to gllA1. 
Sgg LL009 is the only S. gallolyticus strain that lacks a homolog for gallocin A, and instead harbours a variant of 
infantaricin A, here termed gallocin D.
Synthesis and spectrum of inhibition of infantaricin A and gallocin D. The gallocin D1 prepep-
tide encoded by gllD1 is 51 amino acids and the D2 pre-peptide encoded by gllD2 is 52 amino acids in length, 
while the active peptides are predicted to be 30 and 29 amino acids, respectively. We synthesised both D1 and 
D2 peptides for further characterisation, the mass of the synthesized D2 peptide matched the observed mass of 
3,021 Da. The D2 peptide displays no activity in a well diffusion assay against Lb. delbrueckii ssp bulgaricus, while 
Table 1.  Antibiotic resistance results. EFSA guidelines do not have specific values for S. gallolyticus. Values for 
S. thermophilus and the defined values for “other Gram positive” bacteria displayed.
Antibiotic
S. gallolyticus 
LL009 profile EFSA S. thermophilus EFSA other Gram +ve
Gentamicin 8 8 8 32 4
Kanamycin 128 128 128 64 16
Streptomycin 64 64 64 64 8
Neomycin 32 32 32 n/a n/a
Tetracycline 0.5 0.5 0.5 4 2
Erythromycin 0.06 0.03 0.03 2 0.5
Clindamycin 0.12 0.06 0.06 2 0.25
Chloramphenicol 2 2 2 4 2
Ampicillin 0.25 0.25 0.25 2 1
Penicillin 0.12 0.12 0.12 n/a n/a
Vancomycin 0.5 0.5 0.5 4 2
Quinupristin-dalfopristin 1 1 1 n/a n/a
Linezolid 1 1 1 n/a n/a
Trimethroprim 2 2 2 n/a n/a
Ciprofloxacin 1 1 1 n/a n/a
Rifampicin 0.25 0.12 0.25 n/a n/a
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the D1 peptide has solo activity, which is enhanced when in a 1:1 combination with D2. When tested against 
pathogenic bacteria, both peptides are required for activity. The infantaricin A peptides were also synthesized 
and it was found that the peptides cross-complemented each other, A1/D2 or D1/A2 (Fig. 4).
A number of indicator organisms were tested to determine the spectrum of activity, using both the overlay 
method on a plate and a well diffusion assay using the synthesized peptide (Table 4). The bacteriocin was active 
against a narrow range of indicator organisms that included the clinically important pathogens S. pneumoniae 
and vancomycin resistant enterococci (VRE) strains but was inactive against other unrelated pathogenic and 
commensal bacteria. The minimum inhibitory concentration (MIC) of the gallocin D peptide was assessed at 
1.56 µM against VRE EC300.
Streptococcus gallolyticus DPC6501 was isolated from a porcine jejunum in a previous study and is reported 
to produce a  bacteriocin30. This strain was tested for sensitivity to Sgg LL009 and the synthesized gallocin D 
peptides. The overlay assay of Sgg LL009 showed zones of inhibition against S. gallolyticus DPC6501 and a zone 
of inhibition from 15 µM gallocin D peptides was observed in a well diffusion assay (Fig. 5).
Resistance development in VRE EC300 against gallocin D. The microtitre plates from the MIC 
determination experiment were plated in an attempt to identify growth of VRE EC300. Following 24 h growth, 
VRE EC300 cells from the control and wells containing 100 µM gallocin D, the highest concentration included, 
were spread plated on BHI, and then sub-cultured into fresh BHI. At 24 h, the sub-cultured broths were seri-
ally diluted and plated. The bacteriocin treated cells showed no growth at any dilution, while the untreated cells 
reached 4.9 × 108 cfu ml−1. At this concentration and inoculum, no colonies were found following treatment with 
gallocin D.
For the time-kill assay actively growing VRE EC300 at  108 cfu ml−1 was treated with gallocin D at 15.6 µM, 
10 × the MIC value. Within the first 4 h, VRE EC300 was undetectable in all treated broths, while the untreated 
control remained at  108 cfu ml−1. At 6 h, VRE EC300 was detected in treated broths while at 24 h the treated 
broths were lower than the untreated control at  107 cfu ml−1 (Fig. 6).
Discussion
The bacteriocin operons within the S. gallolyticus subspecies gallolyticus of the SBSEC were found to be generally 
highly conserved, with the exception of the newly isolated Sgg LL009 which lacks the gallocin A structural genes 
and has different structural genes and a putative immunity gene at this locus. The structural genes in Sgg LL009 
are variants of genes in an infantaricin A producing S. infantarius LP90 (Sii LP90), and its associated immunity 
gene. Infantaricin A is encoded by an operon with seven predicted bacteriocin structural genes, of which infC 
shows sequence homology to the gallocin A structural genes. Sgg LL009 is the only genome analysed found to 
lack genes for gallocin A/infantaricin C, and contain a variant of previously identified infantaricin A. In a BLAST 
Figure 2.  Organisation of the predicted operon encoding the bacteriocin, aligned to the operon of (A) type 
strain S. gallolyticus DSM 16,831, with below alignment of structural genes; gllA2 and gllD2 show 42% identity, 
gllA1 and gllD1 share 22% identity. (B) S. infantarius LP90 infantaricin ABCDEFG bacteriocin cluster. Genes in 
line with the same background colour are homologous and the amino acid percent identity is indicated.
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search limited to the SBSEC, no gallocin D hits were found outside of the S. gallolyticus or S. infantarius species 
and only one potential gallocin A homolog was identified in S. macedonicus.
Gallocin A is a two-peptide bacteriocin which has been reported to give S. gallolyticus a competitive advantage 
in conditions found in in the gut of patients with CRC. This bacteriocin is absent from closely related species, but 
we identified possible homologs in S. infantarius strains, and gllA2 was found in S. gallolyticus ssp macedonicus 
together with a gene with 60% identity to gllA1. High genome plasticity has been reported in the SBSEC and S. 
gallolyticus is reported to have retained the largest genome and highest functional capacity. Two human isolates 
of S. infantarius, NCTC 13,760 and ATCC BAA-102 possess the infantaricin ABCDEFG bacteriocin operon 
while the dairy isolate Sii CJ18 does not have the complete operon. Sgg LL009 and Sii LP90 were isolated from 
goat and water buffalo raw milk samples, respectively. In previous comparative genomics studies, high numbers 
of IS elements were found in these species. The organisation of the operon and high sequence identity between 
Table 2.  In silico analysis of the predicted function of each gene involved in bacteriocin production.
Orf Length (aa) Blast hit Query cover (%) E-value
Percent 
identity Accession no
1 75 Bacteriocin, hypothetical protein [Streptococcus gallolyticus] 100 3.00E−45 100.00 WP_074595821.1
2 454 Two-component system, AgrA family, sensor histidine kinase AgrC [Streptococcus gallolyticus] 100 0 99.12 WP_074595819.1
3 255 Response regulator transcription factor [Streptococcus gallolyticus] 100 0 99.61 WP_081341218.1
4 97 Enterocin A Immunity [Streptococcus gallolyticus] 100 1.00E−63 100.00 WP_074581674.1
5 75 Hypothetical protein SGADD03_00501 [Streptococcus gallolyticus] 100 1.00E−45 98.67 WP_061458100.1
6 103 Enterocin A Immunity protein [Streptococcus gallolyticus subsp. gallolyticus ATCC 43143] 100 6.00E−68 100.00 WP_003066564.1
7 99 DUF3884 family protein putative bacteriocin [Streptococcus gallolyticus subsp. gallo-lyticus ATCC 43143] 100 2.00E−64 97.98 WP_009854998.1
8 46 Competence stimulating peptide (CSP) precursor [Streptococcus gallolyticus] 100 1.00E−24 100.00 AQP43123.1
9 436 Histidine kinase of the competence regulon,ComD1 [Streptococcus gallolyticus subsp. gallolyticus DSM 16831] 100 0 99.54 WP_058621373.1
10 243 Response regulator transcription factor [Streptococcus gallolyticus] 100 3.00E−178 100.00 WP_013643488.1
11 108 Multispecies: LytTR family transcriptional regulator [Streptococcus] 100 8.00E−72 99.07 WP_009855002.1
12 451 Glycosyl transferase family 2 [Streptococcus gallolyticus subsp. gallolyticus ATCC BAA-2069] 95 0 98.84 WP_013643489.1
13 99 Hypothetical protein BTR42_10805 [Streptococcus gallolyticus subsp. gallolyticus DSM 16831] 100 1.00E−66 100.00 AQP43128.1
14 60 Hypothetical protein BTR42_10810 [Streptococcus gallolyticus subsp. gallolyticus DSM 16831] 100 9.00E−37 100.00 WP_013643491.1
15 69 Helix-turn-helix transcriptional regulator [Streptococcus orisratti] 100 2.00E−41 98.55 WP_018375366.1
16 337 Bacteriocin biosynthesis protein [Streptococcus gallolyticus] 100 0 96.74 WP_077497732.1
17 71 Hypothetical protein SAMN02910295_0951 [Streptococcus gallolyticus] 100 3.00E−40 98.59 WP_074595803.1
18 224 InfAE-Imm [Streptococcus infantarius subsp. infantarius] 100 2.00E−141 92.86 WP_006531871.1
19 51 Infantaricin A1 [Streptococcus infantarius subsp. infantarius] 100 5.00E−28 98.04 WP_006531870.1
20 52 Infantaricin A2 [Streptococcus infantarius subsp. infantarius] 70 3.00E−24 90.38 WP_006531869.1
21 85 Hypothetical protein [Streptococcus gallolyticus] 100 3.00E−50 98.82 WP_074628192.1
22 715 ABC-type bacteriocin transporter [Streptococcus gallolyticus] 100 0 99.44 WP_074595798.1
23 411 Bacteriocin secretion accessory protein, partial [Streptococcus gallolyticus] 100 0 99.27 WP_061458107.1
Table 3.  Genomes analysed in this study.
Species Strain NCBI reference Source
Streptococcus gallolyticus ssp. gallolyticus
DSM 16831 NZ_CP018822.1 Koala feces
ATCC 43143 NC_017576.1 Human blood
ATCC BAA-2069 NC_015215.1 Human blood
UCN34 NC_013798.1 Human blood
LL009 Raw goat milk
Streptococcus infantarius ssp. infantarius
CJ18 NC_016826.1 Suusac fermented camel milk
LP90 KJ475434.1 Water buffalo milk
NCTC13760 NZ_UHFP00000000.1 Human faeces
ATCC BAA-102 NZ_ABJK00000000.2 Human GIT
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Figure 3.  Comparison of the operons of all strains analysed. Genes in line with the same background colour 
are homologous (> X% amino acid sequence identity indicated), while the white background represents genes 
for which no homologs have been found between strains; box 1 shows the immunity protein and infantaricin A 
in S. infantarius strains and immunity protein and the gallocin D variant in S. gallolyticus LL009; box 2 shows 
potential homologs for gallocin A.
Figure 4.  (A) Mixing gallocin D and infantaricin A peptides indicates that any combination of the alpha and 
beta peptides results in activity, concentration in µM across the top. ‘Rugby ball’ shape seen between wells 
indicates where the peptides meet following diffusion into the media, showing complementary activity. (B) 
Alignment of sequences of the prepeptides from both species, the double glycine cleavage point is underlined.
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genes suggests that transfer of bacteriocin structural genes occurred between these strains due to adaptive pres-
sure in the microbe-rich environment of the  gut21. Sgg LL009 has unique structural genes which are produced 
within the gallocin D operon.
The association between S. gallolyticus and CRC is not fully  understood31, but it is thought that the conditions 
in the colon when tumours are present provide a suitable niche for S. gallolyticus if competitors can be controlled 
with gallocin A. Gallocin A and gallocin D share similar characteristics and target organisms. Gallocin A produc-
tion is enhanced in the presence of secondary bile acids, a known risk factor of CRC. The cell free supernatant of 
S. gallolyticus UCN34 shows no activity in a well diffusion assay in the absence of a detergent or secondary bile 
acids, a feature that is also observed for Sgg LL009 producing gallocin  D10. S. gallolyticus mutants lacking gllA1 
and gllA2 do not have the same colonisation advantage in tumour-bearing mice, leading to the conclusion that 
S. gallolyticus is not a causative factor of CRC but does promote its acceleration if pre-malignant tumours are 
present and the strain colonises. Both gallocin A and gallocin D target enterococci, with enhanced bacteriocin 
production in CRC conditions. This suggests that Sgg LL009 could well retain the colonisation advantage seen 
in S. gallolyticus UCN34 in CRC conditions, despite their distinct amino acid sequences.
Table 4.  Indicator organisms with growth conditions. Inhibition is represented by relative 
activities + 0.5–2 mm zone, ++ 2–4 mm zone, +++  > 4 mm zone + , and no inhibition −.
Indicator organism Growth medium Incubation conditions Inhibition
Actinomyces neuii LMG 19524t BHI 37°,  O2− −
Actinomyces radingae LMG 15960t BHI 37°,  O2− −
Enterococcus faecium EC300 BHI 37°,  O2+ +++
Enterococcus faecium EC520 BHI 37°,  O2+ +++
Enterococcus faecium EC533 BHI 37°,  O2+ +
Enterococcus faecium EC571 BHI 37°,  O2+ ++
Escherichia coli DPC 6,054 BHI 37°,  O2+ −
Enterococcus faecalis E265 BHI 37°,  O2+ +
Lactobacillus delbrueckii ssp. bulgaricus LMG 6,901 MRS 37°,  O2− +++
Lactobacillus helveticus ATCC11454 MRS 37°,  O2− −
Listeria innocua DPC 1,768 BHI 37°,  O2+ +
Listeria monocytogenes DPC 3,572 BHI 37°,  O2+ −
Salmonella enterica ser. Typhimurium DPC 6,046 BHI 37°,  O2+ −
Staphylococcus aureus R963 BHI 37°,  O2+ −
Streptococcus agalactiae LMG 14,694 BHI 37°,  O2+ −
Streptococcus pnuemoniae DSM 24,048 BHI 37°,  O2+ ++
Streptococcus pnuemoniae DSM 14,377 BHI 37°,  O2+ +++
Streptococcus pnuemoniae DSM 20,566 BHI 37°,  O2+ +++
Streptococcus pnuemoniae DSM 25,971 BHI 37°,  O2+ ++
Streptococcus gallolyticus DPC 6,501 BHI 37°,  O2+ +++
Figure 5.  (A) Sgg LL009 colonies showing inhibition of Sgg DPC6501 (indicator organism). (B) Well diffusion 
assay using synthesized gallocin D against Sgg DPC6501, concentration in µM indicated above each well.
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The operons in the various S. gallolyticus strains were strikingly similar with the exception of the bacteriocin 
structural genes, suggesting that these bacteriocins would be subject to similar regulation and would be produced 
under similar conditions. Whether this strain would have a protective effect in the colon is unclear. It is likely, 
due to their similar target organisms and production characteristics, that this strain of S. gallolyticus producing 
gallocin D would occupy the same niche as S. gallolyticus producing gallocin A. Further studies are required to 
assess if this gallocin D producing S. gallolyticus is able to colonise and accelerate cancer development.
This work confirms horizontal gene transfer of bacteriocin structural genes between members of the SBSEC, 
which have been shown to have high genome  plasticity18. Sgg LL009 and Sii CJ18 are both dairy isolates and both 
show the most “unusual” operons; the structural and immunity genes of Sgg LL009, and Sii CJ18 has the lowest 
number of bacteriocin structural genes of all the Sii strains. This hints at a role for these bacteriocins, gallocin D 
and infantaricin A, in streptococcal strains colonising ruminant animals. Further identification of bacteriocin 
producers from the SBSEC could lead to further evidence of shuffling of bacteriocin structural genes.
A further strain of bacteriocin producing S. gallolyticus from our culture collection, S. gallolyticus DPC6501, 
is sensitive to gallocin D, which strongly indicates that the genomic annotation of the immunity protein is cor-
rect. This is the only predicted immunity protein present in Sgg LL009 and absent in related S. gallolyticus strains 
and also the only immunity protein shared between Sgg LL009 and the infantaricin A producer. Sgg LL009 is not 
inhibited by Sgg DPC6501, this strain has not been sequenced, but is known to be a bacteriocin producer from 
previous  work30. We hypothesise that Sgg LL009 is not susceptible to gallocin A, but that synthesized gallocin D 
could provide an alternative strategy for the control of S. gallolyticus infections.
The application of gallocin D is not limited to its potential role in controlling the growth of other S. gallolyticus 
strains in CRC. It is a narrow spectrum bacteriocin with potent activity against VRE, opportunistic pathogens 
that are particularly relevant in hospital settings, for patients who are immunocompromised and those under 
antibiotic treatment for  endocarditis32. VRE can infect the urinary tract, surgical wounds or the bloodstream and 
are spread by direct contact. Many patients who develop VRE infections have underlying illnesses and due to 
antibiotic resistance this infection can lead to serious problems or  fatalities33. The kill curve of gallocin D shows 
it can reduce the numbers of VRE from  108 cfu ml−1 to undetectable levels in two hours, though the cells regrow 
after 8 h. Importantly, when added to growing cells at  105 cfu ml−1, which is regarded as a clinical infection, the 
VRE EC300 did not recover and no resistant colonies were found. This suggests that the mode of action of this 
bacteriocin is related to cell contact; if the bacteriocin is present in the right ratio to cells the infection can be 
cleared. The MIC and resistance testing results for gallocin D show that it completely kills VRE EC300 when 
present at  105 cfu ml−1, and gallocin D is present at the MIC of 1.56 µM.
conclusions
A combination of laboratory and in silico analyses led to the discovery and characterisation of gallocin D, a class 
IIb bacteriocin with activity against VRE, S. pneumoniae, and a related strain of S. gallolyticus. Gallocin D is a 
variant of infantaricin A produced by closely-related S. infantarius species. The operon is similar to those found 
in other S. gallolyticus genomes, with the exception of the structural and immunity genes. This work highlights 
the shuffling of bacteriocin structural genes within these closely related species. Gallocin D could be applied for 
treatment of VRE infections, and potentially for the control of other species of S. gallolyticus.
Materials and methods
Bacterial strains culture conditions. S. gallolyticus LL009 was isolated from raw goat milk produced in 
New Zealand on S. thermophilus agar at 42 °C. S. gallolyticus LL009 was routinely cultured under aerobic condi-
tions at 37 °C, in brain heart infusion (BHI) medium (Oxoid Ltd., Basingstoke, Hampshire, United Kingdom), 
all other reagents were sourced from Sigma-Aldrich (Wicklow, Ireland) unless otherwise stated. Indicator strains 
used and their incubation conditions are listed in Table 3.
Figure 6.  Kill curve of VRE EC300 using 15.6 µM gallocin D. EC300 + samples contain bacteriocin (each 
representing a biological triplicate), EC300 has no bacteriocin (control).
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Draft genome sequencing. DNA was extracted using a Genelute bacterial genomic DNA kit (Sigma) and 
prepared for sequencing using a Nextera XT kit (Illumina) for library preparation. DNA was quantified using a 
Qubit 2.0 fluorometer. Sequencing was carried out using an Illumina MiSeq platform with paired-end 2 × 300 
base pair reads at the Teagasc Sequencing Centre, Teagasc Food Research Centre Moorepark. Assembly was per-
formed de novo using SPADES and automatically annotating using  GAMOLA34. The whole genome sequence 
was run through Bagel4 and antiSMASH to search for bacteriocin genes. The genome was also compared to 
other available S. gallolyticus and S. infantarius genomes from NCBI listed in Table 4.
Antimicrobial activity assays. Sgg LL009 was grown on BHI agar and incubated overnight at 37 °C. Sgg 
LL009 was assayed against various indicator organisms, listed in Table 4 along with incubation conditions. Plates 
were overlaid with MRS agar (7.5 g L−1 agar) seeded with L. bulgaricus LMG6901 and incubated overnight at 
37 °C, anaerobically. Activity was defined by a clearing in the overlay medium.
Overnight cultures were centrifuged and filtered to obtain cell free supernatant (CFS). MRS agar was seeded 
with an overnight culture of L. bulgaricus LMG6901 and wells were made. Both broth and CFS were added to 
the wells in 50 µl volumes. Plates were incubated overnight at 37 °C. Triton X-100 was added to CFS at 1% con-
centrations. All assays were performed in triplicate. The well diffusion method was repeated using synthesized 
gallocin D, using peptides alone and in combination (1:1).
Minimum inhibitory concentration. Minimum inhibitory concentration (MIC) determinations of gal-
locin D (D1D2) were carried out in triplicate in microtitre plates as previously  described35. Briefly, VRE EC300 
was grown overnight in BHI broth at 37 °C and subcultured at 0.5% into fresh broth. The strain was grown to 
OD600 of 0.5 and diluted to a final concentration of  105 cfu ml−1 in a final volume of 100 µl. Synthesized gal-
locin D peptides in a 1:1 ratio were made up to 100 µM concentration and serially diluted to a concentration 
of 0.98 µM in sterile water. The peptide solutions were added at 100 µl volumes to the VRE broth. The plate 
was incubated at 37 °C for 16 h, MIC was determined as the lowest concentration causing visible inhibition of 
growth.
Resistance testing. In order to assess resistance development by VRE EC300, the MIC protocol was 
repeated. The microtitre wells containing 100 µM gallocin D and control wells were plated directly and cultured 
in fresh BHI broth. At 24 h, the sub-cultured broths were serially diluted and plated. The whole microtitre plate 
was reincubated for a further 48 h and observed for cloudiness indicative of growth.
Kill curve. VRE EC300 was grown overnight in BHI and adjusted in fresh BHI to a final concentration of 
 108  cfu  ml−1. Synthesized gallocin D was added at concentration of 10 × MIC (15.6  µM) to triplicate testing 
broths, and sterile water added to control VRE broths. Samples were taken at multiple time points until 8 h and 
again at 24 h, serial diluted in MRD and plated on BHI medium. Plates were incubated for 24 h at 37 °C before 
colonies were enumerated.
Colony mass spectrometry. Colony MALDI-TOF MS (Axima  TOF2 MALDI-TOF mass spectrometer, 
Shimadzu Biotech) was used to determine the molecular mass of the peptides present on the surface of colonies 
as follows: cells were first mixed in 70% (v/v) 2-propanol/0.1% TFA (IPA) and vortex mixed, the sample was 
separated by centrifugation at 14,000 r.p.m and the supernatant was subsequently used for analysis. A MALDI 
target plate was precoated with CHCA matrix solution, 0.5 µL of the supernatant from the cell extract was then 
placed on the target and a final layer of matrix solution was added. Positive-ion linear mode was used to identify 
the peptide masses on an Axima  TOF2 MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK). 
The masses detected were then compared to those of known bacteriocins.
Peptide synthesis and purification. Peptides were synthesised by microwave-assisted solid phase pep-
tide synthesis (MW-SPPS) performed on a Liberty Blue microwave peptide synthesizer (CEM Corporation. 
Mathews, NC, USA). Gallocin D1 was synthesized on a H-Cys(Trt)-HMPB)-ChemMatrix resin and Gallocin 
D2 was synthesised on H-Phe-HMPB-ChemMatrix resin (PCAS BioMAtrix Inc., Quebec, Canada). Crude pep-
tide was purified using RP-HPLC on a Semi Preparative Jupiter Proteo C12 (10 × 250 mm, 4 µ, 90 Å) column 
(Phenomenex, Cheshire, UK) running acetonitrile 0.1% TFA gradients specific to the peptide of interest. Frac-
tions containing the desired molecular mass were identified using MALDI-TOF-mass spectrometry in positive 
in linear mode and were pooled and lyophilized on a Genevac HT 4X lyophiliser (Genevac Ltd., Ipswich, UK).
Growth curve. A single colony of VRE was inoculated into BHI medium and incubated at 37 °C for 16 h, 
and subcultured at 1% into fresh medium. Samples were taken at 0, 2, 4, 5, 6, 7, 8 and24 hours for  OD600 and 
plating. OD was read in duplicate, 100 µl was serially diluted in MRD to  10–8 and plated on BHI agar. Plates were 
incubated for 24 h and enumerated. Experiments were completed in triplicate, each with technical duplicates.
Antibiotic resistance. The MIC value of sixteen antibiotics was assessed using the VetMIC Lact-1 and 
Lact-2 MIC determination plates (National Veterinary Institute, Sweden). The antibiotics tested were ampicillin, 
penicillin, vancomycin, erythromycin, virginiamycin, tetracycline, clindamycin, chloramphenicol, kanamycin, 
gentamycin, streptomycin, neomycin, linezolid, rifampicin, ciprofloxacin, and trimethoprim. Briefly, colonies 
were resuspended in MRD at a concentration of ~ 1 × 108 cfu ml−1 and transferred into ISO-MRS broth for a 
final inoculum of 5 × 105 cfu ml−1. VetMIC plates were inoculated with 100 µl, sealed and incubated for 24 h. 
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Evidence of growth was determined using a backlight, MIC value is the lowest concentration completely inhibit-
ing growth. EFSA guidelines do not have specific values for S. gallolyticus, so values were interpreted using S. 
thermophilus values and the defined values for other Gram positive  bacteria36.
Exopolysaccharide screening. Multiple screening methods were used to test for ropy and non-ropy type 
EPS; ruthenium red agar, the loop touch test and sucrose-supplemented MRS. Ruthenium red was filter steri-
lised, added to cooling MRS agar at 0.08% and mixed before pouring plates27. For the loop touch test, a sterile 
loop was touched to a single colony and slowly pulled away. A string between the loop and colony was recorded 
as a positive result. 10% (w/v) sucrose and 10% (w/v) lactose supplemented MRS plates were autoclaved at 
121 °C for 15 min and poured, a mucous phenotype was characterised as a positive result.
Proteolysis. 10% reconstituted skim milk (RSM) was autoclaved at 121 °C for 5 min and combined with a 
3% (w/v) agar solution, autoclaved at 121 °C for 15 min, the solutions were allowed to cool to ~ 45 °C and com-
bined 1:1, and poured into petri dishes. Previously grown Sgg LL009 was re-streaked onto the RSM plates and 
incubated at 37 °C for 48 h, plates were viewed every 24 h. Proteolysis was defined as clear zones surrounding 
colonies.
Hemolysis. Tryptic Soy Agar was prepared 5% v/v sterile defibrinated horse blood was pre-warmed, added 
to the sterile agar and mixed well before pouring. Previously grown Sgg LL009 was re-streaked onto the plates 
and incubated for 72 h, plates were viewed every 24 h for lysis, defined as a clearing or discolouration of the agar.
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